Adimab turns profit on deals with GSK, Biogen

Adimab signed its first-ever technology transfer and license agreement that gives a partner broad access to the Lebanon, New Hampshire-based company's antibody discovery platform with GlaxoSmithKline and immediately followed the first deal with a second, expanding Adimab's existing relationship with Biogen Idec.